Stefania Oliva

9PUBLICATIONS
77CO-AUTHORS
HaematologyPredictive and prognostic markersMedical mycologyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 21, 2026
Durable Response in Histiocytic Sarcoma After Allogeneic Stem Cell Transplantation: A Case Report.

Stefania Oliva, Jessica Gill, Elia Boccellato

|Feb 12, 2025
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials.

Qian Shi, Bruno Paiva, Levi D Pederson

|Dec 04, 2023
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.

Mattia D'Agostino, Giuseppe Bertuglia, Delia Rota-Scalabrini

|Jun 14, 2023
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.

Enrique M Ocio, Aurore Perrot, Pierre Bories

|Jun 06, 2022
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.

Luca Bertamini, Stefania Oliva, Delia Rota-Scalabrini

|Sep 14, 2021
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.

Pieter Sonneveld, Meletios A Dimopoulos, Meral Beksac

Pageof 2

Frequent Collaborators

3 joint publications

Mario Boccadoro

3 joint publications

Francesca Gay

2 joint publications

Renato Zambello

2 joint publications

Vincent van de Velden